Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 6/20 | 0.58 |
| ▸ | HTR1D known ✓ | P28221 | 4/20 | 0.56 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.54 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.48 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.48 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.48 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.43 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.42 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.39 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.39 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.39 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321122 | 0.99 | HTR1B (0.59) | HTR1BHTR1DNR2E1HTR6EGFR | |
| Hydrochloric Acid SCHEMBL8869642 | 0.91 | HTR1B (0.47) | HTR1BHTR1DNR2E1HTR6EGFR | |
| Hydrochloric Acid SCHEMBL3466984 | 0.83 | HTR1B (0.60) | HTR1BHTR1DHTR1AHTR1FKMT2A | |
| SCHEMBL980209 | 0.82 | HTR1B (0.61) | HTR1BHTR1DHTR1AHTR1FKMT2A | |
| SCHEMBL7031093 | 0.82 | HTR1B (0.61) | HTR1BHTR1DHTR1AHTR1FKMT2A | |
| SCHEMBL2301469 | 0.82 | HTR1B (0.61) | HTR1BHTR1DHTR1AHTR1FKMT2A | |
| SCHEMBL7415658 | 0.81 | HTR1F (0.63) | HTR1BHTR1DHTR1AHTR1FKMT2A | |
| Bromide SCHEMBL7027435 | 0.81 | HTR1B (0.60) | HTR1BHTR1DHTR1AHTR1FKMT2A | |
| Hydrochloric Acid SCHEMBL7025647 | 0.81 | HTR1A (0.47) | HTR1BHTR1DHTR1AHTR1FKMT2A | |
| SCHEMBL8646717 | 0.80 | HTR1B (0.48) | HTR1BHTR1DHTR1AHTR1FKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0674621-B1 | ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | VERNALIS LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020032192-A1 | Treatment of vasodilatory headache | VERNALIS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| EP-1104292-A2 | TREATMENT OF VASODILATORY HEADACHE | Vernalis Limited (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009099-A2 | TREATMENT OF VASODILATORY HEADACHE | VERNALIS LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
| US-5962501-A | HEADACHES | SMITHKLINE BEECHAM, P.L.C. (GB) | 1999-10-05 | — | — | US | disclosed |
| US-5917054-A | ALKYLATING ENANTIOMER OF 3-AMINO-6-CARBOXAMIDO-1,2,3,4-TETRAHYDROCARBAZOLE OR A SALT | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-06-29 | — | — | US | disclosed |
| US-5827871-A | VASODILATION DISORDERS, ESPECIALLY MIGRAINE HEADACHES; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM PLC (GB) | 1998-10-27 | — | — | US | disclosed |
| EP-0603432-B1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1998-10-21 | — | — | EP | disclosed |
| EP-0591280-B1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5650426-A | Enantiomers of carbazole derivatives as 5-HT.sub. 1-like agonists | SMITHKLINE BEECHAM PLC (GB) | 1997-07-22 | — | — | US | disclosed |
| US-5637611-A | Medicaments | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-06-10 | — | — | US | disclosed |
| US-5618948-A | TREATMENT OF 6-CARBOXAMIDO-3-METHYLAMINO-1,2,3,4-TETRAHYDROCARBAZOLE WITH 2-PYRROLIDONE-5-CARBOXYLIC ACID, CRYSTALLIZATION | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-04-08 | — | — | US | disclosed |
| US-5618947-A | SEPARATING THE RACEMIC MIXTURE BY CHROMATOGRAPHY | SMITHKLINE BEECHAM, P.L.C. (GB) | 1997-04-08 | — | — | US | disclosed |
| US-5616603-A | TREATING MIGRAINES | SMITHKLINE BEECHAM PLC (GB) | 1997-04-01 | — | — | US | disclosed |
| US-5464864-A | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-11-07 | — | — | US | disclosed |
| EP-0674621-A1 | ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014772-A1 | ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
| EP-0603432-A1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032192-A1 | Treatment of vasodilatory headache | CNR1, CNR2, EDNRA | HTR1B 71/4885HTR1D 26/4885HTR6 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.